Enliven Therapeutics Q4 2024 net loss $23.2M; cash $313.4M; pipeline milestones set for 2025

Enliven Therapeutics, Inc.

Net loss $23.2M in Q4 2024 ($19.4M in Q4 2023); full year 2024 net loss $89.0M ($71.6M in FY2023).
Cash, cash equivalents and marketable securities $313.4M as of Dec 31, 2024; cash runway into mid-2027.
R&D expenses $20.7M in Q4 2024 ($17.9M Q4 2023); full year $80.8M ($64.6M FY2023).
ELVN-001 Phase 1 data expected mid-2025; ELVN-002 Phase 1 data expected H2 2025; FDA orphan drug designation.
First patient dosed in Japanese Phase 1 trial for ELVN-001; ELVN-002 combination trials enrolling.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.